Main > > >DIABETES. *

---

Analysis of:
Albumin to Creatinine Ratio (ACR) Results
in 5 min. at Point of Care &
Hemoglobin A1c (HbA1c) Results in 3 min.
at Point of Care.
USA Launch Date: 2018. 05.31.
(*) Company : Abbott.
TradeMark: Afinion
UpDate: 2018. 06.01.




Cardio.>Diabetes Type II. Heart Failure (HF). Hospitalization Risk Reduction: Dapagliflozin Tablets.
Mechanism: SGLT2 Inhibition.
EU Approval Date : 2019. 08.
USA Approval Date: 2019. 10.21.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 10.23.




Cardio.>HyperTriGlyceridemia. (HTG). Icosapent Ethyl [Ethyl EicosaPentaenoic Acid (E-EPA)]. Indications:
Indication (1): HTG>Treat.>Diet+ Icosa-
pent Ethyl Capsules.
Indication (2): CardioVascular (CV)
Events (in Adult Pa-
tients with HTG & CV
DIS. or Diabetes) RISK
Reduction: Statin+Icosa-
pent Ethyl Capsules.
CV Events:
- Coronary Revascularization.
- Myocardial Infarction (MI)
- Stroke
- Unstable Angina requiring hospitali-
zation.
CA Approval Date (2): 2020. 01.02.
USA Approval Date (1): 2012.
USA Approval Date (2): 2019. 12.13.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 01.03.




Cardio.>Myocardial Infarction. Preven-tion. Diabetes Type II Patients: Semaglutide.
USA Approval Date: 2020. 01.16.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 01.18.




Prognostics. Report for Type 2 Diabetes.
Offering Start Date: 2019. 03.10.
(*) Company: 23andMe Inc.
UpDate: 2020. 01.20.


>DIABETES. *'s products
This section has no products